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Humoral hypercalcemia of malignancy (HHM) is rarely associated with cholangiocar-
cinoma (CC), and represents dismal prognosis. A 63-year-old male was admitted for
evaluation of an intrahepatic mass. He was diagnosed with HHM associated with 
locally advanced CC. As the tumor responded to the concurrent chemoradiotherapy
with capecitabine and cisplatin, serum calcium level was normalized. However, 
according to the disease progression, he suffered recurrence of HHM and he expired
approximately one year after initial diagnosis. A 68-year-old male who presented with
abdominal pain was diagnosed with metastatic CC. After the eighth cycle of gemc-
itabine and cisplatin, progression of the disease was found with HHM. He was treated
with the best supportive care, until his demise approximately one month after the 
diagnosis of HHM. We report on two cases of HHM associated with CC that demon-
strate strong correlation between hypercalcemia and disease burden.
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Introduction
Hypercalcemia is a life threatening complication of malig-
nant disease, and has been reported to occur in approxi-
mately 20% to 30% of patients with malignancies at some
time during the course of their disease [1]. Although hyper-
calcemia associated with cancer can be caused by various
mechanisms, humoral hypercalcemia of malignancy (HHM)
is the most common cause, accounting for 80% of occur-
rences. Parathyroid hormone-related peptide (PTH-rP) has
been identified as a mediator of HHM [2].
Cholangiocarcinoma (CC) is a relatively uncommon
tumor, accounting for 10% to 15% of hepatobiliary malignan-
cies and 3% of gastrointestinal tract cancers. The prognosis
for advanced cholangiocellular carcinoma is very poor. In a
recent large randomized controlled phase III study, gemc-
itabine plus cisplatin combination chemotherapy was bene-
ficial in terms of progression-free survival and overall
survival, as compared with gemcitabine monotherapy [3],
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and has become the standard treatment for advanced CC;
however, the median overall survival with combination
chemotherapy arm is still less than one year. 
HHM, which has rarely been reported in patients with CC,
represents a marker of poor prognosis of the disease. In this
case report, we present two cases of CC, showing the signs,
symptoms, laboratory findings, and disease course consistent
with HHM. 
Case Reports
1. Case 1
A 63-year-old male patient was referred to our hospital for
evaluation of an intrahepatic mass discovered during a 
routine health checkup in August 2010. He had no past 
medical history. Except for corrected serum calcium level of
12.1 mg/dL (normal range, 8.5 to 10.5 mg/dL), the blood test
at initial presentation was not remarkable. His electrocardio-
gram showed normal sinus rhythm and there were no other
hypercalcemia-associated symptoms or signs. An abdomino-
pelvic computed tomography (CT) scan showed a large mass
measuring 13 cm in size, suggesting CC with intrahepatic
metastases and invasion of the left portal vein and hepatic
vein (Fig. 1A). Sono-guided liver biopsy was performed and
the pathologic diagnosis showed poorly differentiated carci-
noma, highly suggestive of CC. Because there was no distant
metastasis on the positron emission tomography CT scan, we
made a diagnosis of locally advanced intrahepatic CC. Given
the tumor’s unresectable status and the patient’s good 
performance, we decided to treat him with radiotherapy 
concurrent with capecitabine 1,000 mg/m2 twice daily on
days 1-14 and cisplatin 60 mg/m2 day once every three
weeks. The first two cycles of chemotherapy were adminis-
tered with radiotherapy, a total dose of 45 Gy at the main
mass in the liver. 
Follow-up CT scan after concurrent chemoradiotherapy
(CCRT) showed marked improvement in the patient’s tumor
Fig. 1. (A) Computed tomography (CT) scan at initial diagnosis showing intrahepatic metastases measuring 13 cm and 
invasion of the Lt. portal vein and hepatic vein. (B) Six months later, follow up CT scan after radiation therapy concurrent
with capecitabine plus cisplatin showed marked improvement of tumor status.
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Fig. 2. Patient progress, including changes in corrected
serum calcium level and tumor marker. CEA, carcinoem-
bryonic antigen; CA 19-9, cancer antigen 19-9.
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status (Fig. 1B). In parallel with the improvement of tumor
status, serum calcium level showed a decrease to the normal
range (Fig. 2). We continued to administer the same treat-
ment regimen, and the response was maintained for nine
months, until May 2011, when a follow-up CT scan showed
liver metastasis progression. Carcinoembryonic antigen
(CEA) and cancer antigen 19-9 (CA 19-9) level were elevated
to 48.17 U/mL (normal range, 0 to 5 U/mL) and 97.0 ng/mL
(normal range, 0 to 37 ng/mL), respectively. At the same
time, his corrected serum calcium level increased again to
11.1 mg/dL. The suppressed PTH level (5.1 pg/mL; normal
range, 15 to 65 pg/mL) with elevated PTH-rp level (6.7
pmol/L; normal range, 0 to 1.1 pmol/L) confirmed the diag-
nosis of recurrent HHM. We treated the patient with intra-
venous hydration and pamidronate. Hypercalcemia was
resolved in five days and the patient was performing well
without any signs or symptoms related to hypercalcemia,
therefore, he was treated with second-line chemotherapy
with gemcitabine. 
After two cycles of gemcitabine, a follow-up CT scan
showed liver mass progression and newly developed
hematogenous lung metastasis. The corrected serum calcium
level was elevated even higher (11.8 mg/dL). Although 
hypercalcemia was normalized after medical treatment, his
poor performance hindered him from receiving additional
chemotherapy. Instead, he was treated with the best support-
ive care. When he visited the outpatient clinic three weeks
later, he was in a state of somnolence and oral intake was not
possible due to severe nausea and vomiting. His corrected
serumcalcium level rose upto 15.3 mg/dL. 
Eventually, the patient died on 10 August 2011, almost one
year after initial diagnosis of CC with HHM. 
2. Case 2
A 68-year-old male patient presented with weight loss of
6 kg over two months and abdominal pain for one week. He
had no past medical history. Ultrasonography performed at
the local hospital showed a mass lesion in the liver, and he
was referred to our hospital. An abdominopelvic CT scan
showed CC with innumerable liver to liver metastases and
node metastases. Sono-guided liver biopsy was performed
and the pathologic diagnosis was adenocarcinoma, either
primary or metastatic. Because no primary mass was found
by esophagogastroduodenoscopy and colonoscopy, we
made a diagnosis of CC with liver metastasis and began
treatment with palliative chemotherapy, gemcitabine plus
cisplatin. His tumor was stable until 28 June 2011, when he
visited the outpatient clinic for the eighth cycle of gemc-
itabine and cisplatin approximately six months after his 
initial diagnosis.  
At that time, his blood test was remarkable for a corrected
serum calcium level of 11.8 mg/dL. Otherwise, there were
no symptoms or signs related to hypercalcemia and he was
in good performance status. After receiving treatment with
intravenous hydration and pamidronate, he received the 8th
cycle of chemotherapy as scheduled. We scheduled an 
appointment for another visit to recheck his condition as well
as his serum calcium level. When he returned to the outpa-
tient clinic one week later, his mental status was somewhat
somnolent. A blood test showed an aggravated corrected
serum calcium level of 14.1 mg/dL and decreased liver func-
tion; aspartate aminotransferase was three times the normal
level (102 IU/mL; normal range, 13 to 34 IU/mL), alkaline
phosphatase was 340 U/L (normal range, 38 to 115 U/L), and
albumin was decreased to 2.8 mg/dL (normal range, 3.3 to
5.3 mg/dL). Other blood tests were not remarkable. CT scan
revealed aggravation of the main mass and a metastatic 
lesion in the liver, and newly developed ascites. CEA and CA
19-9 levels were elevated to 981.32 ng/mL and 7,450 U/mL,
respectively. As the PTH level was suppressed to 4.8 pg/mL
and PTH-rP level was increased to 8.3 pmol/L, we were able
to make a diagnosis of HHM. He was hospitalized and
treated with intravenous hydration and pamidronate. After
admission, his hypercalcemia was corrected to a certain 
degree, but never returned to normal range. Despite 
improvement in his mental status, his performance status did
not recover from Eastern Cooperative Oncology Group 3.
Hence we discontinued chemotherapy and treated him with
the best supportive care until he expired on 24 July 2011, only
approximately one month after diagnosis of HHM.
Discussion
HHM is usually found in patients with squamous cell 
carcinoma as of the head and neck, esophagus, and lung.
Other tumors commonly associated with HHM include
breast, renal, bladder, and ovarian cancers, human T-cell
lymphotropic virus-1 lymphoma, and some endocrine 
tumors. 
CC is rarely associated with HHM. In an early retrospec-
tive analysis conducted in 1982, when measurement of PTH-
rP was not available, Oldenburg et al. [4] reported hyper-
calcemia of unknown origin in seven out of 40 patients
(17.5%) with CC. Among them, immunoreactive parathyroid
hormone (iPTH) concentration levels were measured in only
two patients. Both patients had normal or low PTH levels,
and the authors concluded their works by suggesting that 
secretion of iPTH-like peptide is the possible mechanism for
their findings [4].
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Third, consistent with the previous reports, our reports
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ment and led to a fatal outcome when it developed in a 
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cancer therapy.
In conclusion, we herein report on two cases of humoral
hypercalcemia of malignancy associated with CC. Although
the condition’s dismal prognosis can be partly overcome by
more proactive treatment, its manifestation implicates 
massive overall disease burden and an adverse outcome
when the tumor itself is not controlled.
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